Cardiofaciocutaneous syndrome: genes and variants
Explore variant evidence for Cardiofaciocutaneous syndrome across 5 analyzed proteins (BRAF, MAP2K1, MAP2K2, KRAS, NRAS). Linked ClinVar records include 49 pathogenic or likely pathogenic variants, 80 variants of uncertain significance and 25 with conflicting classifications.
Coverage includes proteins already analyzed in CATVariant, not every gene involved in this condition. Database links are associations, not an assessment of clinical gene–disease validity. Computable evidence prioritizes variants for expert review and does not reclassify them. Source labels are pooled across this disease family.
Data updated 2026-11-05. Automated aggregation, not a clinical review date.
Download variant evidence (CSV)
Genes linked to Cardiofaciocutaneous syndrome
BRAF: Serine/threonine-protein kinase B-raf
It relays activated RAS signals through MEK and ERK to control proliferation, differentiation, and survival. Activating variants, especially V600E, drive melanoma and several other cancers and create sensitivity to pathway-directed therapies.
17 ClinVar pathogenic / likely pathogenic and 27 uncertain variants in BRAF have source records linked to Cardiofaciocutaneous syndrome. Association strength is not clinical gene validity.
MAP2K1: Dual specificity mitogen-activated protein kinase kinase 1
It phosphorylates ERK1 and ERK2 downstream of RAF and thereby propagates RAS-MAPK growth and developmental signals. Activating somatic variants occur in several cancers, while germline activating variants can cause cardio-facio-cutaneous syndrome and related RASopathies.
14 ClinVar pathogenic / likely pathogenic and 21 uncertain variants in MAP2K1 have source records linked to Cardiofaciocutaneous syndrome. Association strength is not clinical gene validity.
MAP2K2: Dual specificity mitogen-activated protein kinase kinase 2
It works with MEK1 to activate ERK signaling downstream of RAS and RAF. Germline activating variants can cause cardio-facio-cutaneous syndrome, while acquired activation can support oncogenic MAPK signaling and drug resistance.
9 ClinVar pathogenic / likely pathogenic and 55 uncertain variants in MAP2K2 have source records linked to Cardiofaciocutaneous syndrome. Association strength is not clinical gene validity.
KRAS: GTPase KRas
A small GTPase that acts as a molecular switch in the RAS-MAPK signaling pathway. By cycling between GDP- and GTP-bound states, it relays growth and survival signals, and activating KRAS variants are common drivers of cancer.
9 ClinVar pathogenic / likely pathogenic and 2 uncertain variants in KRAS have source records linked to Cardiofaciocutaneous syndrome. Association strength is not clinical gene validity.
NRAS: GTPase NRas
Its active GTP-bound state drives RAF-MEK-ERK and PI3K signaling downstream of growth-factor receptors. Somatic activating variants are common drivers of melanoma, leukemia, and other cancers, while germline activating variants can cause Noonan syndrome.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in NRAS have source records linked to Cardiofaciocutaneous syndrome. Association strength is not clinical gene validity.
Where Cardiofaciocutaneous syndrome variants cluster
- BRAF Protein kinase (positions 457–717): 16 of 17 ClinVar pathogenic / likely pathogenic variants, 2.8× more than its size predicts (a length-based count, not a validated hotspot).
ClinVar pathogenic and likely pathogenic variants linked to Cardiofaciocutaneous syndrome
| Variant | Position | Protein part | Clinical label |
|---|---|---|---|
| KRAS G12A | 12 | Pathogenic / likely pathogenic (★★) | |
| MAP2K2 K61E | 61 | Pathogenic / likely pathogenic (★★) | |
| MAP2K2 K61N | 61 | Pathogenic / likely pathogenic (★★) | |
| BRAF K601Q | 601 | Protein kinase | Pathogenic / likely pathogenic (★★) |
| BRAF K601I | 601 | Protein kinase | Pathogenic / likely pathogenic (★★) |
| MAP2K1 P124L | 124 | Protein kinase | Pathogenic / likely pathogenic (★★) |
| MAP2K1 G128V | 128 | Protein kinase | Pathogenic / likely pathogenic (★★) |
| MAP2K1 E203A | 203 | Protein kinase | Pathogenic / likely pathogenic (★★) |
| MAP2K1 E203K | 203 | Protein kinase | Pathogenic / likely pathogenic (★★) |
| MAP2K2 F57L | 57 | Pathogenic / likely pathogenic (★★) | |
| BRAF A481E | 481 | Protein kinase | Pathogenic / likely pathogenic (★★) |
| BRAF L525Q | 525 | Protein kinase | Pathogenic / likely pathogenic (★★) |
| BRAF G534R | 534 | Protein kinase | Pathogenic / likely pathogenic (★★) |
| BRAF V600L | 600 | Protein kinase | Pathogenic / likely pathogenic (★★) |
| BRAF D638E | 638 | Protein kinase | Pathogenic / likely pathogenic (★★) |
| KRAS P34R | 34 | Effector region | Pathogenic / likely pathogenic (★★) |
| KRAS G60S | 60 | Pathogenic / likely pathogenic (★★) | |
| MAP2K2 N126D | 126 | Protein kinase | Pathogenic / likely pathogenic (★★) |
| MAP2K2 P128L | 128 | Protein kinase | Pathogenic / likely pathogenic (★★) |
| MAP2K2 G132D | 132 | Protein kinase | Pathogenic / likely pathogenic (★★) |
| BRAF D565E | 565 | Protein kinase | Pathogenic / likely pathogenic (★★) |
| KRAS R68S | 68 | Pathogenic / likely pathogenic (★★) | |
| KRAS D119N | 119 | Pathogenic / likely pathogenic (★★) | |
| KRAS K147E | 147 | Pathogenic / likely pathogenic (★★) | |
| MAP2K1 P124A | 124 | Protein kinase | Pathogenic / likely pathogenic (★) |
| MAP2K1 G128A | 128 | Protein kinase | Pathogenic / likely pathogenic (★) |
| MAP2K1 E203Q | 203 | Protein kinase | Pathogenic / likely pathogenic (★) |
| MAP2K1 M256T | 256 | Protein kinase | Pathogenic / likely pathogenic (★) |
| MAP2K2 Q60H | 60 | Pathogenic / likely pathogenic (★) | |
| BRAF G460R | 460 | Protein kinase | Pathogenic / likely pathogenic (★) |
| BRAF G464A | 464 | Protein kinase | Pathogenic / likely pathogenic (★) |
| BRAF L485W | 485 | Protein kinase | Pathogenic / likely pathogenic (★) |
| BRAF K499N | 499 | Protein kinase | Pathogenic / likely pathogenic (★) |
| BRAF W531L | 531 | Protein kinase | Pathogenic / likely pathogenic (★) |
| BRAF F583L | 583 | Protein kinase | Pathogenic / likely pathogenic (★) |
| KRAS A59L | 59 | Pathogenic / likely pathogenic (★) | |
| MAP2K1 A52P | 52 | Pathogenic / likely pathogenic (★) | |
| MAP2K1 F129L | 129 | Protein kinase | Pathogenic / likely pathogenic (★) |
| MAP2K1 Y130N | 130 | Protein kinase | Pathogenic / likely pathogenic (★) |
| MAP2K2 A56D | 56 | Pathogenic / likely pathogenic (★) | |
| BRAF S215F | 215 | RBD | Pathogenic / likely pathogenic (★) |
| BRAF Q709R | 709 | Protein kinase | Pathogenic / likely pathogenic (★) |
| MAP2K1 F53Y | 53 | Pathogenic / likely pathogenic (★) | |
| MAP2K1 P89T | 89 | Protein kinase | Pathogenic / likely pathogenic (★) |
| KRAS G12S | 12 | Pathogenic / likely pathogenic | |
| MAP2K1 P124Q | 124 | Protein kinase | Pathogenic / likely pathogenic |
| MAP2K2 V64G | 64 | Pathogenic / likely pathogenic | |
| BRAF A712D | 712 | Protein kinase | Pathogenic / likely pathogenic |
| KRAS Y71H | 71 | Pathogenic / likely pathogenic |
Which prediction tools work for Cardiofaciocutaneous syndrome
Observed separation of ClinVar pathogenic / likely pathogenic from benign / likely benign variants (AUROC × 100). This benchmark is not a clinical recommendation.
- REVEL: 94 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- AlphaMissense: 92 out of 100
- CATVariant: 86 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- ESM1b (LLR): 86 out of 100
- MutPred: 84 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- VARITY: 81 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- PolyPhen-2: 79 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- CADD: 78 out of 100
- SIFT: 76 out of 100
- MetaSVM: 76 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MetaLR: 75 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- phyloP: 73 out of 100
- DMS / MaveDB: 71 out of 100
- EVE: 71 out of 100
- phastCons: 55 out of 100
Same protein, different disease
- RASopathy also has ClinVar records linked to BRAF variants; they fall partly in the same places as the Cardiofaciocutaneous syndrome variants (36 pathogenic / likely pathogenic).
- Cardio-facio-cutaneous syndrome also has ClinVar records linked to BRAF variants; they fall mostly in different places as the Cardiofaciocutaneous syndrome variants (26 pathogenic / likely pathogenic).
- Noonan syndrome also has ClinVar records linked to BRAF variants; they fall partly in the same places as the Cardiofaciocutaneous syndrome variants (11 pathogenic / likely pathogenic).
- Noonan syndrome and Noonan-related syndrome also has ClinVar records linked to BRAF variants; they fall partly in the same places as the Cardiofaciocutaneous syndrome variants (10 pathogenic / likely pathogenic).
- Non-small cell lung carcinoma also has ClinVar records linked to BRAF variants; they fall partly in the same places as the Cardiofaciocutaneous syndrome variants (9 pathogenic / likely pathogenic).
- RASopathy also has ClinVar records linked to MAP2K1 variants; they fall partly in the same places as the Cardiofaciocutaneous syndrome variants (14 pathogenic / likely pathogenic).
- Cardio-facio-cutaneous syndrome also has ClinVar records linked to MAP2K1 variants; they fall mostly in different places as the Cardiofaciocutaneous syndrome variants (6 pathogenic / likely pathogenic).
- RASopathy also has ClinVar records linked to MAP2K2 variants; they fall in the same places as the Cardiofaciocutaneous syndrome variants (9 pathogenic / likely pathogenic).
- RASopathy also has ClinVar records linked to KRAS variants; they fall partly in the same places as the Cardiofaciocutaneous syndrome variants (23 pathogenic / likely pathogenic).
- Noonan syndrome also has ClinVar records linked to KRAS variants; they fall partly in the same places as the Cardiofaciocutaneous syndrome variants (16 pathogenic / likely pathogenic).
- Non-small cell lung carcinoma also has ClinVar records linked to KRAS variants; they fall partly in the same places as the Cardiofaciocutaneous syndrome variants (5 pathogenic / likely pathogenic).
- Cardio-facio-cutaneous syndrome also has ClinVar records linked to KRAS variants; they fall in the same places as the Cardiofaciocutaneous syndrome variants (4 pathogenic / likely pathogenic).
Diseases related to Cardiofaciocutaneous syndrome
- RASopathy, also linked to BRAF, KRAS, MAP2K1, MAP2K2 and 1 more
- Noonan syndrome, also linked to BRAF, KRAS, MAP2K1, MAP2K2 and 1 more
- Noonan syndrome and Noonan-related syndrome, also linked to BRAF, KRAS, MAP2K1, MAP2K2 and 1 more
- Hypertrophic cardiomyopathy, also linked to BRAF, MAP2K1, MAP2K2 and NRAS
- Cardio-facio-cutaneous syndrome, also linked to BRAF, KRAS, MAP2K1 and MAP2K2
- Costello syndrome, also linked to BRAF, MAP2K1, MAP2K2 and NRAS
- Vascular malformation, also linked to BRAF, KRAS, MAP2K1 and NRAS
- Melanoma, also linked to BRAF, MAP2K1, MAP2K2 and NRAS
- Colorectal cancer, also linked to BRAF, KRAS and NRAS
- Non-small cell lung carcinoma, also linked to BRAF, KRAS and MAP2K1
- Multiple myeloma, also linked to BRAF, KRAS and NRAS
- Neurofibromatosis, also linked to MAP2K1 and MAP2K2
Frequently asked questions
Which genes have records linked to Cardiofaciocutaneous syndrome?
This view contains 5 analyzed proteins: BRAF, MAP2K1, MAP2K2, KRAS, NRAS. Links come from clinical records and association databases. They do not imply that every listed gene is a validated cause, and missing genes may not yet be analyzed.
What do the clinical classifications mean?
Linked records include 49 pathogenic or likely pathogenic variants, 80 variants of uncertain significance and 25 with conflicting classifications. Labels summarize source records; multi-condition records may not make a separate assertion for this disease. Check the original record and review status.
Does the evidence score change a VUS classification?
No. 0 VUS or conflicting variants reach the likely-pathogenic points range on the computable criteria available here. This is a research prioritization signal, not a clinical classification. Patient, family and other required evidence may be missing.
Can I download the variant evidence?
Download the CSV for all 200 variants in the selected disease scope, including clinical labels, review status, evidence criteria, predictor scores, functional measurements and population frequency where available.
About this data
Variant–disease links come from ClinVar, Open Targets and UniProt, pooled from eligible public CATVariant analyses of each human protein. Evidence scores use the ACMG/AMP Bayesian points scale with computable criteria only (position among known disease variants, rarity in gnomAD, calibrated predictors, deep mutational scanning); there is no family or patient data, so they prioritise variants for expert review and never classify them.
Download every variant as CSV · Browse all diseases · Methods · About the Center